Gastrointestinal and renal side effects of bisphosphonates: Differentiating between no proof of difference and proof of no difference

Journal of Endocrinological Investigation

Volumn 38, Issue 2, 2015, Pages 189-192

  Fadda, V ^a   Maratea, D ^a   Trippoli, S ^a   Messori, A ^a  

^a HTA Unit Area Vasta Centro Toscana Regional Health System   (Italy)

Author keywords

Bisphosphonates; Equivalence; Osteoporosis; Safety

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; ATTRIBUTABLE RISK; BAYES THEOREM; COMPARATIVE STUDY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DYSFUNCTION; META ANALYSIS (TOPIC); NEPHROTOXICITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STATISTICAL EQUIVALENCE; STATISTICAL MODEL; CHEMICALLY INDUCED; GASTROINTESTINAL DISEASES; KIDNEY DISEASES; META ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY DISEASES; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921823147     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0211-5     Document Type: Article

References (20)

1. Mascha EJ (2010) Equivalence and noninferiority testing in anesthesiology research. Anesthesiology 113(4):779-781
2. Ahn S, Park SH, Lee KH (2013) How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. Radiology 267(2):328-338
3. Messori A, Fadda V, Gatto R, Maratea D, Trippoli S (2014) Differentiating between "no proof of difference" and "proof of no difference" for new oral anticoagulants. BMJ 348:g1955. Doi: 10.1136/bmj.g1955
4. Walker E, Nowacki AS (2011) Understanding equivalence and noninferiority testing. J Gen Intern Med 26(2):192-196
5. Migliore A, Broccoli S, Massafra U, Cassol M, Frediani B (2013) Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. Eur Rev Med Pharmacol Sci 17(5):658-667
6. Tadrous M, Wong L, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM (2014) Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int 25(4):1225-1235
7. Messori A, Fadda V, Maratea D, Trippoli S, Marinai C (2014) Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods. J Endocrinol Invest 37(8):769-773
8. Fadda V (2014) Gastrointestinal adverse events of bisphosphonates. PubMedCommons. http://www.ncbi.nlm.nih.gov/pubmed/24287510#cm24287510-5074. Accessed 2 Jul 2014
9. Lumley T (2002) Network meta-analysis for indirect treatment comparisons. Stat Med 21(16):2313-2324
10. Hoaglin DC, Hawkins N, Jansen JP et al (2011) Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices - part 2. Value Health 14:429-437
11. Sobieraj DM, Cappelleri JC, Baker WL, Phung OJ, White CM, Coleman CI (2013) Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review. BMJ Open 3(7). Doi: 10.1136/bmjopen-2013-003111
12. Greco T, Landoni G, Biondi-Zoccai G, D'Ascenzo F, Zangrillo A (2013) A Bayesian network meta-analysis for binary outcome: how to do it. Stat Methods Med Res [Epub ahead of print]
13. Messori A (2014) Bayesian models implemented under Winbugs: can they be considered the new standard for conducting a network meta-analysis? PubMed Commons. http://www.ncbi.nlm.nih.gov/pubmed/23970014#cm23970014-6256. Accessed 15 Sep 2014
14. NICE Clinical Guidelines, No. 92 (2010) National clinical guideline centre - acute and chronic conditions (UK). London Royal College of Physicians (UK). http://www.ncbi.nlm.nih.gov/books/NBK116530/. Accessed 14 Aug 2014
15. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50(6):683-691
16. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA (2014) Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 189(3):250-255
17. Norman G, Monteiro S, Salama S (2012) Sample size calculations: should the emperor's clothes be off the peg or made to measure? BMJ 23(345):e5278. Doi: 10.1136/bmj.e5278
18. Tanaka S, Kinjo Y, Kataoka Y, Yoshimura K, Teramukai S (2012) Statistical issues and recommendations for noninferiority trials in oncology: a systematic review. Clin Cancer Res 18(7):1837-1847
19. Yanik B, Bavbek N, Yanik T, Inegöl I, Kanbay M, Turgut FH, Uz E, Akçay A (2007) The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. Ren Fail 29(4):471-476
20. Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S (2013) Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 28(10):2049-2059. Doi: 10.1002/jbmr.2058